BET inhibitor resistance emerges from leukaemia stem cells

Nature

Volumn 525, Issue 7570, 2015, Pages 538-542

  Fong, Chun Yew ^a,b   Gilan, Omer ^a,b   Lam, Enid Y N ^a   Rubin, Alan F ^b,c   Ftouni, Sarah ^a   Tyler, Dean ^a,b   Stanley, Kym ^a   Sinha, Devbarna ^a   Yeh, Paul ^a,b   Morison, Jessica ^d   Giotopoulos, George ^d   Lugo, Dave ^e   Jeffrey, Philip ^e   Lee, Stanley Chun Wei ^f   Carpenter, Christopher ^g   Gregory, Richard ^e   Ramsay, Robert G ^a,b   Lane, Steven W ^h   Abdel Wahab, Omar ^f   Kouzarides, Tony ⁱ   Johnstone, Ricky W ^a,b   Dawson, Sarah Jane ^a,b   Huntly, Brian J P ^d   Prinjha, Rab K ^e   Papenfuss, Anthony T ^a,b,c   Dawson, Mark A ^a,b   more..

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d University of Cambridge   (United Kingdom)

^e GLAXOSMITHKLINE   (United Kingdom)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g GLAXOSMITHKLINE   (United States)

^h UNIVERSITY OF QUEENSLAND   (Australia)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; 7 (3,5 DIMETHYL 4 ISOXAZOLYL) 1,3 DIHYDRO 8 METHOXY 1 [1 (2 PYRIDINYL)ETHYL] 2H IMIDAZO[4,5 C]QUINOLIN 2 ONE; BETA CATENIN; HYBRID PROTEIN; MLL AF9 FUSION PROTEIN; PYRVINIUM EMBONATE; SHORT HAIRPIN RNA; TRANSCRIPTOME; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BRD4 PROTEIN, HUMAN; CHROMATIN; GSK525762A; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE;

BLOOD SYSTEM DISORDER; CELLS AND CELL COMPONENTS; CLONE; DISEASE RESISTANCE; DRUG; GENE EXPRESSION; HOMINID; INHIBITOR; METABOLISM; PIGMENT; PROTEIN; RODENT;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CELL CLONE; CELL CYCLE ARREST; COLONY FORMING UNIT GM; CONTROLLED STUDY; CROSS RESISTANCE; DRUG DOSE REDUCTION; FEMALE; HEMATOPOIETIC STEM CELL; IMMORTALIZED CELL LINE; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WNT SIGNALING PATHWAY; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHROMATIN; CYTOLOGY; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; HUMAN; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MOLECULARLY TARGETED THERAPY; ONCOGENE MYC; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; AZEPINES; BENZODIAZEPINES; BETA CATENIN; CELL LINE, TUMOR; CELLS, CULTURED; CHROMATIN; CLONE CELLS; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRIAZOLES; WNT SIGNALING PATHWAY;

EID: 84942531832     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14888     Document Type: Article

References (42)

1. Dawson,M. A., Kouzarides, T.&Huntly,B. J. Targeting epigenetic readers in cancer. N. Engl. J. Med. 367, 647-657 (2012).
2. Shi, J., Vakoc, C. R. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell 54, 728-736 (2014).
3. Herait,P. E. et al.BET-bromodomain inhibitorOTX015shows clinicallymeaningful activity at nontoxic doses: interimresults of an ongoing phase I trial in hematologic malignancies. Cancer Res. 74, CT231 (2014).
4. Dawson, M. A., Kouzarides, T. Cancer epigenetics: from mechanism to therapy. Cell 150, 12-27 (2012).
5. Helin, K., Dhanak, D. Chromatin proteins and modifications as drug targets. Nature 502, 480-488 (2013).
6. Dawson, M. A. et al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional programin acutemyeloid leukemia. Leukemia 28, 311-320 (2014).
7. Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529-533 (2011).
8. Zuber, J. et al.RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528 (2011).
9. Weisberg, E.,Manley, P. W.,Cowan-Jacob, S. W.,Hochhaus, A.&Griffin, J.D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nature Rev. Cancer 7, 345-356 (2007).
10. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010).
11. Holohan, C., Van Schaeybroeck, S., Longley, D. B., Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nature Rev. Cancer 13, 714-726 (2013).
12. Krivtsov, A. V. et al. Transformation fromcommitted progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442, 818-822 (2006).
13. Somervaille, T.C.&Cleary,M. L. Identificationandcharacterizationof leukemia stem cells inmurineMLL-AF9 acutemyeloid leukemia. Cancer Cell 10, 257-268 (2006).
14. Wang, Y. et al. The Wnt/b-catenin pathway is required for the development of leukemia stem cells in AML. Science 327, 1650-1653 (2010).
15. Krivtsov, A. V. et al. Cell of origin determines clinically relevant subtypes of MLLrearranged AML. Leukemia 27, 852-860 (2013).
16. Valent, P. et al. Cancer stem cell definitions and terminology: the devil is in the details. Nature Rev. Cancer 12, 767-775 (2012).
17. Eppert, K. et al. Stemcell gene expression programs influence clinical outcome in human leukemia. Nature Med. 17, 1086-1093 (2011).
18. Goardon, N. et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19, 138-152 (2011).
19. Andersson, A. K. et al. The landscape of somatic mutations in infant MLLrearranged acute lymphoblastic leukemias. Nature Genet. 47, 330-337 (2015).
20. Lovén, J. et al. Selective inhibition of tumor oncogenes by disruption of superenhancers. Cell 153, 320-334 (2013).
21. Yeung, J. et al. b-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 18, 606-618 (2010).
22. Jamieson, C. H. et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351, 657-667 (2004).
23. Thorne, C. A. et al.Small-molecule inhibition ofWnt signaling through activation of casein kinase 1a. Nature Chem. Biol. 6, 829-836 (2010).
24. Knoechel, B. et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nature Genet. 46, 364-370 (2014).
25. Rathert, P. et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature http://dx.doi.org/10.1038/nature14898 (2015).
26. Zhao, W. et al. A new bliss independencemodel to analyze drug combination data. J. Biomol. Screen. 19, 817-821 (2014).
27. Hu, Y., Smyth, G. K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 347, 70-78 (2009).
28. Li, H., Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
29. Amarasinghe, K. C., Li, J., Halgamuge, S. K. CoNVEX: copy number variation estimation in exome sequencing data using HMM. BMC Bioinformatics 14 (Suppl. 2), S2 (2013).
30. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576 (2012).
31. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature Biotechnol. 31, 213-219 (2013).
32. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
33. McLaren, W. et al. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 26, 2069-2070 (2010).
34. Karolchik, D. et al. The UCSC Table Browser data retrieval tool. Nucleic Acids Res. 32, D493-D496 (2004).
35. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
36. Tsirigos, A., Haiminen, N., Bilal, E., Utro, F. GenomicTools: a computational platform for developing high-throughput analytics in genomics. Bioinformatics 28, 282-283 (2012).
37. Smyth, G. in Bioinformatics and Computational Biology Solutions using R and Bioconductor (eds Gentleman, R. et al.) 397-420 (Springer, 2005).
38. Benjamini, Y., Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289-300 (1995).
39. Liao, Y., Smyth,G.K.&Shi, W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 41, e108 (2013).
40. Liao, Y.,Smyth,G.K.&Shi, W. featureCounts:an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923-930 (2014).
41. Wu, D. et al. ROAST: rotation gene set tests for complex microarray experiments. Bioinformatics 26, 2176-2182 (2010).
42. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).